News & Insights

Meet Our Founders: Glenn Gaston

Glenn Gaston

Axolo Medical (formerly XR Technologies) – SEED Spring 2024

Published August 14, 2024

As part of our ‘Meet Our Founders’ series today, we introduce Glenn Gaston, Managing Partner of Axolo Medical (formerly XR Technologies) based in Charlotte, NC. Axolo Medical is an innovative virtual reality platform designed to prevent and cure phantom limb pain in amputees through scientifically proven brain rehabilitation known as TBR.

Q: What problem are you trying to solve and what influenced you to start your company?

A: We strive to solve phantom limb pain which affects up to 80% of amputees in the world. Our inspiration is our patients, as we run one of the busiest amputee clinics in the world and seeing their pain drives us to find a cure.

Q: What are you most excited about right now? What keeps you up at night?

A: Seeing patients faces when they remove the VR headset and say their pain is the lowest it has been in years still gives me chills. Sharing in their relief reminds us why we became doctors. Trying to run a new start up business and not squander the opportunity to commercialize this amazing opportunity to help all amputees keeps me up at night.

Q: How will your NC IDEA grant funds advance your company?

A: These funds have already allowed us to start our website, begin to commercialize our product, file our provisional patents, bring on an FDA consultant and will enable us to sell and pilot our first 10 devices by the end of the year. Thank you NC IDEA!!

 

While visiting Charlotte, Glenn recommends:

  • For the outdoor enthusiasts, when visiting Charlotte visit the White Water Center, a Panthers game or Romare Bearden Park. Southend offers a trendy food and brewery scene while Fig Tree and Barringtons are some hidden gems for local upscale dining.

 

Support Axolo Medical and Glenn by:

  • We welcome any and all advice on navigating the FDA waters for clearance as software as a medical device, contacts within the VA and medical community to promote our novel product and further insight into non-dilutive funding opportunities.